Mannan-binding lectin in malignancy

► Possible cancer associations of mannan-binding lectin (MBL) are discussed. ► MBL may play various roles, depending on the type of disease, mode of treatment and other factors. ► Review includes data concerning solid tumours and haematological malignancies. Complement may play a dual role in cancer...

Full description

Saved in:
Bibliographic Details
Published in:Molecular immunology 2013-08, Vol.55 (1), p.16-21
Main Authors: Swierzko, Anna S., Kilpatrick, David C., Cedzynski, Maciej
Format: Article
Language:English
Subjects:
Animals
Cancer
Complement Pathway, Mannose-Binding Lectin - genetics
Complement Pathway, Mannose-Binding Lectin - physiology
Humans
Innate immunity
Mannan-binding lectin
Mannose-Binding Lectin - genetics
Mannose-Binding Lectin - metabolism
Mannose-Binding Lectin - physiology
MBL2
Medical Oncology - methods
Medical Oncology - trends
Models, Biological
Neoplasms - etiology
Neoplasms - genetics
Neoplasms - metabolism
Protein Multimerization - genetics
Protein Multimerization - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:► Possible cancer associations of mannan-binding lectin (MBL) are discussed. ► MBL may play various roles, depending on the type of disease, mode of treatment and other factors. ► Review includes data concerning solid tumours and haematological malignancies. Complement may play a dual role in cancer: it may contribute either to the development or to the inhibition of tumour growth. Its components may be candidate biomarkers facilitating the disease detection, its progress or effectiveness of therapy. Additionally, complement deficiencies may increase the risk of infections and contribute to the higher mortality, especially in patients undergoing aggressive chemotherapy. In this paper, possible cancer associations of one of the factors activating complement via the lectin pathway, mannan-binding lectin (MBL), are discussed.
ISSN:0161-5890
1872-9142
DOI:10.1016/j.molimm.2012.09.005